Abstract:Background: Aggressive thyroid carcinoma (ATC) usually loses radioiodine avidity to iodine-131 ( 131 I) due to the downregulation of sodium/iodide symporter (NIS). The expression of thyroid stimulating hormone receptor (TSHR) is more persistent than NIS and the administration of recombinant human thyroid stimulating hormone (rhTSH) promotes de novo NIS synthesis. Hence, exploring methods integrating 131 I with rhTSH might be a feasible therapeutic strategy for selective delivery of 131 I into thyroid cancer to fortify the effect of radioiodine ablation. Methods: The 131 I, poly (lactic-co-glycolic acid) (PLGA) and rhTSH were used to synthesize of the 131 I-PLGA-rhTSH nanoparticles. The characteristics of the 131 I-PLGA-rhTSH nanoparticles was determined using a light microscopy, scanning electron microscopy (SEM), autoradiography and immunofluorescence (IF) staining. The diameter of the 131 I-PLGA-rhTSH nanoparticles was measured with a Mastersizer 3000, and the encapsulation efficiency (EF) of 131 I in 131 I-PLGA-rhTSH nanoparticles and the radioactivity of a single nanoparticle were determined. Then, the mouse tumor xenograft model was established, and the biodistribution and effect of 131 I-PLGA-rhTSH nanoparticles on apoptosis of thyroid cance cells were investigated in vivo. Thereafter, the role of 131 I-PLGA-rhTSH nanoparticles in cell viability using cell counting kit-8 and lactate dehydrogenase (LDH) release assays. Subsequently, the underlying mechanism of 131 I-PLGA-rhTSH nanoparticles in reducing cell viability was assessed using immunostaining, boyden invasion assays and phalloidin staining. Results: Our results showed that the method of developing nanoparticles-encapsulated 131 I using poly (lactic-co-glycolic acid) (PLGA) and modified with rhTSH ( 131 I-PLGA-rhTSH), was a feasible avenue for the integration of 131 I and rhTSH. Meanwhile, the encapsulation efficiency (EF) of 131 I-PLGA-rhTSH nanoparticles was approximately 60%, and the radioactivity of a single nanoparticle was about 1.1×10-2 Bq. Meanwhile, the 131 I-PLGA-rhTSH nanoparticles were selectively delivered into, gradually enriched and slowly downregulated in xenograft tumor after the administration of 131 I-PLGA-rhTSH nanoparticles through tail vein in mouse tumor xenograft model. Thereafter, the tumor weight was significantly reduced after the administration of 131 I-PLGA-rhTSH nanoparticles. Subsequently, the application of 131 I-PLGA-rhTSH nanoparticles facilitated apoptosis and attenuated immobilization via inhibiting F-actin assembling of FTC-133 cells. Conclusion: The present study develops a suitable approach integrating 131 I and rhTSH, and this strategy is a feasible regimen enhancing the effect of radioiodine ablation for the treatment of thyroid cancer.

Combining Transfer of Ttf-1 and Pax-8 Gene: A Potential Strategy to Promote Radioiodine Therapy of Thyroid Carcinoma

Efficient Multicistronic Co-Expression of Hnis and Htpo in Prostate Cancer Cells for Nonthyroidal Tumor Radioiodine Therapy.

Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells.

Therapeutic Effects of Adenovirus-Mediated CD and NIS Expression Combined with Na131I/5-FC on Human Thyroid Cancer.

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

Inhibiting Β-Catenin Expression Promotes Efficiency of Radioiodine Treatment in Aggressive Follicular Thyroid Cancer Cells Probably Through Mediating NIS Localization.

Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.

Re-induction of cell differentiation and 131I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection

Radioiodide uptake and therapy of lung cancer cells mediated by human sodium iodide symporter gene

The Glial Fibrillary Acidic Protein Promoter Directs Sodium/iodide Symporter Gene Expression for Radioiodine Therapy of Malignant Glioma

Combination of all-trans retinoic acid with tributyrin induced human folliculat thyroid carcinoma

Advances of Radioiodine Therapy of Tumor Induced by Sodium Iodide Symporter Gene

Experimental Study of Baculovirus-Mediated Transfer of the Thyroid Sodium/iodide Symporter Gene into Thyroid Cancer for Targeted Radiotherapy

Efficacy of lentiviral-mediated transfection of hTSHR in poorly differentiated thyroid carcinoma cell line.

Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in Thyroid Carcinoma Patients

Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells

Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications

Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene

Preparation of a Recombinant Adeno-Associated Virus Vector Encoding the Human NIS Gene and Its Expression in Thyroid Cancer Cell Lines

Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.

Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two-and three-dimensional models